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Abstract
Background: Myocardial infarction (MI) elicits an intense acute inflammatory response that is essential for cardiac
repair. However, an excessive inflammatory response also favors myocardial apoptosis, cardiac remodeling, and
cardiovascular mortality. Omega-3 polyunsaturated fatty acids (ω-3) bear anti-inflammatory effects, which may
mitigate the inflammatory response during MI. This study investigated whether ω-3 intake is associated with
attenuation of the MI-related inflammatory response and cardiac remodeling.
Methods: ST-elevation MI (STEMI) patients (n = 421) underwent clinical, biochemical, nutritional, 3D
echocardiogram, Cardiac Magnetic Resonance imaging (CMRi) at 30 days and 3D echocardiogram imaging at six
months after the MI. Blood tests were performed at day one (D1) and day five (D5) of hospitalization. Changes in
inflammatory markers (ΔD5-D1) were calculated. A validated food frequency questionnaire estimated the nutritional
consumption and ω-3 intake in the last 3 months before admission.
Results: The intake of ω-3 below the median (< 1.7 g/day) was associated with a short-term increase in hs-C-
reactive protein [OR:1.96(1.24–3.10); p = 0.004], Interleukin-2 [OR:2.46(1.20–5.04); p = 0.014], brain-type natriuretic
peptide [OR:2.66(1.30–5.44); p = 0.007], left-ventricle end-diastolic volume [OR:5.12(1.11–23.52)]; p = 0.036] and
decreases in left-ventricle ejection fraction [OR:2.86(1.47–6.88); p = 0.017] after adjustment for covariates. No
differences were observed in the extension of infarcted mass obtained by CMRi.
Conclusion: These findings suggest that a reduced daily intake of ω-3 may intensify outcome-determining
mechanisms after STEMI, such as acute inflammatory response and late left ventricular remodeling.
Trial registration: Clinical Trial Registry number and website: NCT02062554.
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Introduction
Myocardial infarction (MI) elicits an intense acute inflammatory
response due to mechanical stress and ischemia-reperfusion
injury [1]. The generation of pro-inflammatory cyto-
kines via activation of both Nuclear Factor κB
(NF-κB) and Activator Protein-1 (AP-1) transcription
factors represents a central step in the triggering of this
response [2–4]. Although this phenomenon is involved for
cardiac repair, excessive inflammation favors myocardial
apoptosis and cardiac remodeling, thus leading to in-
creased cardiovascular mortality [5–7].
Omega-3 (ω-3) are polyunsaturated fatty acids whose
interactions with human physiology have been reported,
particularly for α-linolenic acid (ALA), eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA). EPA and
DHA components bear anti-inflammatory effects
through two complementary actions: (i) reducing the
content of arachidonic acid products and (ii) downregu-
lating the expression of pro-inflammatory cytokines via
NF-κB and AP-1 inhibition [8–12]. The clinical impact
of this set of mechanisms has been documented in sev-
eral conditions involving the acute phase response.
These included sepsis and chronic inflammatory condi-
tions such as rheumatoid arthritis, multiple sclerosis,
type 1 diabetes mellitus, end-stage renal disease, and
Alzheimer disease [13–19]. Considering the abovemen-
tioned premises, we hypothesized that MI-related in-
flammatory response would be attenuated in individuals
who had enhanced ω-3 intake prior the onset of the cor-
onary event. This assumption is consistent with a previ-
ous randomized controlled trial that showed a decrease
in cardiovascular death with dietary supplementation
with ω-3 [20]. However, it is unclear whether the acute
inflammatory response and cardiac remodeling may be
further subsided by ω-3 intake that is already established
at the time of the inciting event. Therefore, aiming to in-
vestigate whether ω-3 intake is associated with attenu-
ation of the MI-related inflammatory response and
cardiac remodeling, we analyzed a prospective cohort
database originally designed to include the investigation
of nutritional characteristics from 3months prior to 3
months after ST-elevation MI (STEMI) manifestation.
Subjects and methods
Study design and participants
Participants from the Brasília Heart Study (BHS) data-
base were used for this analysis (n = 421). BHS is a an
ongoing prospective observational cohort composed of
STEMI patients admitted to Hospital de Base do Distrito
Federal (Brasília, Brazil) since 2006 [21]. Briefly, BHS in-
clusion criteria were: (i) < 24 h after onset of MI symp-
toms, (ii) ST-segment elevation of at least 1-mm (frontal
plane) or 2-mm (horizontal plane) in 2 contiguous leads
and (iii) increased myocardial necrosis markers above
reference limit of creatine kinase-MB (CK-MB) (25 U/L)
and troponin I (0.04 ng/mL) followed by a decline of
both markers. Participants with new or presumed left
bundle branch block, development of pathological Q
waves without ST-elevation recording or exclusively with
imaging evidence of MI were excluded. Diagram flow is
showed in Fig. 1.
Patients enrolled into the study underwent therapies
based on current guidelines for treatment of acute cor-
onary disease, as indicated by Table 1 data [22]. Attend-
ing physicians, who were blind to the study evaluations,
made all therapeutic decisions.
Clinical evaluation
Participants underwent a structured detailed clinical
questionnaire, anthropometric measurements, blood
collection for biochemical analysis, nutritional, and
imagining evaluation. Ex-smoking status, diabetes and
hypertension were previously defined elsewhere [23].
Coronary reperfusion therapy was assumed when the
participant underwent to percutaneous coronary inter-
vention (PCI) and/or fibrinolytic therapy to restore
the blood flow during MI. Anthropometrical measure-
ments obtained were body weight (kg), height (m),
and waist circumference (WC). Killip and GRACE
scores were evaluated in all enrolled patients. Briefly,
the GRACE risk score is a well-validated multivariable
algorithm for predicting 10-year death risk following
an initial acute coronary syndrome (ACS) [24].
Biochemical analysis
Blood samples were obtained within the first 24 h of MI
symptoms (D1) and at day five of hospitalization (D5).
High-sensitivity C-reactive protein (hs-CRP), urea, cre-
atinine, triglycerides, total cholesterol, high-density lipo-
protein cholesterol (HDL-C), low-density lipoprotein
cholesterol (LDL-C), and glomerular filtration rate
(GFR) were obtained as described elsewhere [23].
Interleukin-2 and B-type natriuretic peptide levels were
quantified by ELISA.
Nutritional evaluation
A food frequency intake questionnaire (FFQ) was used
to estimate nutritional composition and ω-3 intake
[alpha-linolenic acid (ALA), eicosapentaenoic acid
(EPA), and docosahexaenoic acid (DHA)] within the pre-
vious 3-month period. The questionnaire was applied at
admission and at the 3rd month of follow-up. The food
intake was clustered in 62 items divided into 10 groups
(dairy products, eggs and meats, oils, snacks and canned
foods, cereals and vegetables, greens and fruits, desserts
and candies, beverages, diet and light products and
spices). Approximate portions of usual intake of each
item was recalled by patients with the aid of a
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photographic record for dietary surveys and the portion
size was, subsequently, quantified into weights [25].
Total caloric and ω-3 intake were calculated based on a
food composition database of the Brazilian Table of Food
Composition (TACO) [26]. Briefly, TACO is a 399-item
nutritional database with the most consumed foods in
Brazil. Sample of foods were collected in 9 cities in all 5
Brazilian regions. Sampling was performed by mixing
and packing two units of each principal brand collected
in each site. The total units were separated in three dif-
ferent composites of 100–200 g, and then analyzed by
certified laboratories. Contents of total lipids, choles-
terol, saturated, poly- and monounsaturated fatty acids
and trans fats were entered in the database [27]. Quanti-
fication of ω-3 from the questionnaires was performed
by an experienced nutritionist (A.P.R.C.) and values were
omitted from all other study participants.
Echocardiography
Participants underwent 3D Echocardiography at the
first- and sixth-month following MI (iE 33 system; Phi-
lips Medical Systems, Andover, MA) according to
current guidelines [28]. Left ventricle end-diastolic diam-
eter (LVEDD), end-systolic diameter (LVESD), septum
diastolic thickness (SD), and posterior wall diastolic
thickness (PD), left ventricle end-diastolic volume
(LVEDV) and end-systolic volume (LVESV) were ob-
tained in 3D mode, and Ejection fraction (EF) was de-
rived from these volumes.
Cardiac magnetic resonance imagining
Cardiac Magnetic Resonance imaging (CMRi) and CMRi
data analysis were performed according to descriptions
shown in a previous study [29].
Statistical analysis
Normally distributed data were presented as mean ±
SD and skewed data as median and interquartile
range (IQR). Participants were stratified into two
groups according to daily consumption of ω-3 (below
or above the median). Chi-square or two-tailed t tests
were used for comparison of baseline data. Analyses
of covariance (ANCOVA) was used to assess the asso-
ciation between ω-3 consumption and the change (Δ)
of hs-CRP, IL-2 and BNP levels between D1 and D5.
ANCOVA adjusted by covariates was also used to
compare infarcted mass and the change in LVEF and
LVEDV between 30 and 180 days. All analyses of the
changes between D1 and D5 or between the 30th and
the 180th day were additionally adjusted for the base-
line levels in order to attenuate the effect of regres-
sion toward the mean. Multivariate binary logistic
regression was used to evaluate the association be-
tween the dichotomous dependent variable ω-3 intake
below or above the median and the independent vari-
ables Δhs-CPR, ΔIL-2, ΔBNP, ΔLVEF and ΔLVEDV.
These dependent variables were categorized into
below or above their respective medians to bypass the
non-normal distribution and as a strategy to level
their effects sizes, allowing direct comparability be-
tween variables. Stepwise selection of variables was
used to reach the final model using the covariates.
The following covariates were used for ANCOVA and
regression analyses and were selected using bootstrap-
ping based on t test analysis (Table 1): age, gender,
diabetes mellitus, hypertension, coronary reperfusion
therapy, and use of ACE inhibitors/ARBs. Restricted
cubic spline models were used to assess the relation-
ship between daily consumption of ω-3 and hs-CRP
Fig. 1 Diagram flow of study design
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levels. Splines were adjusted by the GRACE score
[24] and plasma peak CKMB levels. The GRACE
score was chosen because its validity was confirmed
as a predictive instrument in STEMI patients and due
to the possibility of aggregating into a single index
relevant covariate, thus reducing the saturation of the
regression models. Statistical analysis was performed
using SPSS®, version 21 for Mac (IBM) and STATA,
version 15.0 for Mac. A two-sided p-value of 0.05 was
considered statistically significant.
Results
Baseline characteristics are shown in Table 1. Partici-
pants who had a daily intake of ω-3 above the median
(≥1.7 g/day) at admission had higher systolic blood pres-
sure, higher levels of triglycerides and higher frequency
Table 1 Baseline characteristics of clinical and laboratory data of participants
Characteristics < 1.7 g n = 204 ≥1.7 g n = 217 p-value
Daily intake of ω-3 at admission (g) 1.0(0.7) 2.7(1.3) < 0.001
Daily intake of ω-3 at 3 months (g) 1.1(0.9) 1.9(1.5) < 0.001
Age, (years) 60 ± 10 58 ± 11 0.256
Gender: female n(%) 52(26) 52(24) 0.717
Diabetes mellitus, n(%) 31(15) 55(25) 0.010
Hypertension, n(%) 113(56) 141(65) 0.044
Previous myocardial infarction, n(%) 21(10) 22(10) 0.957
Previous stroke, n(%) 11(5) 11(5) 0.881
Coronary reperfusion therapy, n(%) 171(84) 194(89) 0.012
Percutaneous coronary intervention (PCI), n(%) 94(46) 100(46) 0.479
Fibrinolytic therapy, n(%) 125(61) 151(70) 0.052
PCI and fibrinolytic therapy, n(%) 53(26) 65(30) 0.190
Current smoking, n(%) 78(38) 83(39) 0.970
Ex smoking, n(%) 59(29) 70(33) 0.440
Drugs previously in use:
Statin, n(%) 13(6) 13(6) 0.861
Calcium channel blocker, n(%) 20(10) 22(10) 0.922
Beta-blocker, n(%) 40(20) 32(14) 0.139
Angiotensin inhibitor drugs (ACEi or ARB), n(%) 66(32) 93(43) 0.026
Aspirin, n(%) 34(17) 33(15) 0.666
HbA1c, (%) 6.0(0.8) 6.1(1.2) 0.830
Glomerular filtration rate, (mL/min) 70(24) 69(25) 0.173
Triglycerides, (mg/dL) 118(90) 147(126) 0.001
LDL-C, (mg/dL) 118 ± 38 121 ± 48 0.538
HDL-C, (mg/dL) 38(13) 36(13) 0.150
Systolic blood pressure, (mmHg) 130(37) 140(40) 0.016
Diastolic blood pressure, (mmHg) 80(30) 85(26) 0.063
Heart rate, (bpm) 75(18) 75(25) 0.415
Time between MI onset and medical care, (minutes) 120(255) 90(182) 0.126
Killip >I, n(%) 20(10) 26(12) 0.470
Peak CK-MB, (UI/L) 161(243) 200(268) 0.070
Troponin, (ng/mL) 2.40(22.36) 1.52(20.16) 0.468
Body Mass Index, (kg/m2) 25.9(5.1) 26.8(5.0) 0.234
Waist circumference, (cm)
Female 95(14) 93(9) 0.164
Male 95(13) 98(12) 0.173
Campos-Staffico et al. Nutrition Journal           (2019) 18:29 Page 4 of 8
of diabetes mellitus, hypertension, and coronary reperfu-
sion therapy as well as the use of ACE inhibitors/ARBs
than their counterparts.
Nutritional follow-up
Three months after STEMI, the food questionnaire was
reapplied in order to evaluate the intake of ω-3 in this
interlude. Participants who originally presented with ω-3
intake below the median (< 1.7 g/day) had no changes in
their ω-3 intake during follow-up (from 1.0(0.7) to
1.1(0.9) g/day; p = 0.572). However, participants who ori-
ginally had an intake of ω-3 above the median (≥1.7 g/
day) reduced their ω-3 intake after STEMI (from 2.7(1.3)
to 1.9(1.5) g/day; p < 0.001). Due to the natural limitation
of the FFQ tool, it is not possible to specify the differ-
ence of 30% (0.8 g). Regardless, after 3 months, the
higher intake group were still consuming significantly
higher amounts of ω-3 (Table 1).
Inflammatory markers
Comparative analyses of inflammatory markers are
shown in Table 2. Participants who consumed ω-3 above
or below the median had equivalent levels of hs-CRP at
D1. Participants who consumed ω-3 above the median
had higher levels of IL-2 at D1 than their counterparts.
The increase in both hs-CRP and IL-2 levels from D1 to
D5 were smaller among those who consumed ω-3 above
the median than their counterparts. All these compara-
tive results remained significant after adjustment for co-
variates as indicated above.
Binary logistic regression models are shown in Table 3
and were used to assess the association between the in-
take of ω-3 and study endpoints. The intake of ω-3 was
inversely associated with increase in hs-CRP and IL-2
levels (Δhs-CRP and ΔIL-2 – Model 1). Both associa-
tions remained significant after full adjustment for co-
variates (Model 2). The addition of smoking habit as
covariate did not change the results.
Restricted cubic spline models were used to assess the
relation between the daily consumption of ω-3 across
changes in hs-CPR levels (Fig. 2). The consumption of
ω-3 was inversely associated with the change in hs-CRP
levels even after fully adjusted analysis (p = 0.01).
Cardiac remodeling
Comparative analyses of BNP levels, infarcted mass,
LVEF, LVEDV and SI are shown in Table 2. No differ-
ence in plasma levels of BNP was observed at D1. How-
ever, BNP levels significantly increased in both
subgroups from D1 to D5 (p < 0.001 and p = 0.032 for
subgroups below and above the median, respectively). In
the subgroup analysis, those who consumed ω-3 levels
Table 2 Comparative levels of inflammatory markers, BNP levels, LVEF and infarcted mass
Characteristics < 1.7 g n = 204 ≥1.7 g n = 217 p-value ANCOVAa
Inflammatory markers
hs-CRP at 1st day, (mg/L) 0.60(1.11) 0.60(0.97) 0.820 0.648
hs-CRP at 5th day, (mg/L) 4.10(6.90) 2.90(4.62) 0.005 0.027
Δhs-CRP, (mg/L)b + 2.80(5.50) + 1.57(4.14) 0.001 0.004
IL-2 at 1st day, (pg/mL) 0.04(1.24) 1.34(2.60) < 0.001 0.036
IL-2 at 5th day, (pg/mL) 5.83(6.55) 5.46(6.30) 0.110 0.224
ΔIL-2, (pg/mL)b +5.36(6.18) + 3.87(6.17) 0.003 0.013
Cardiac remodeling marker
BNP at 1st day, (ng/mL) 0.18(0.13) 0.17(0.17) 0.208 0.099
BNP at 5th day, (ng/mL) 0.35(0.32) 0.21(0.26) < 0.001 0.056
ΔBNP, (ng/mL)b + 0.14(0.27) + 0.07(0.18) 0.003 0.029
Cardiac Magnetic Resonance Imaging and Echocardiography
Infarcted mass, (%) 12.6 ± 7.3 11.8 ± 7.1 0.311 0.406
Infarcted mass, (g) 15.6(9.3) 14.6(11.9) 0.628 0.798
LVEF at 1st month, (%) 55.0 ± 14.8 53.7 ± 13.8 0.590 0.900
LVEF at 6th month, (%) 54.7 ± 12.8 59.9 ± 10.6 0.189 0.609
ΔLVEF, (%)b −1.9 ± 10.7 + 4.5 ± 13.6 0.165 0.010
LVEDV at 1st month, (mL) 89.8 ± 38.0 96.6 ± 32.6 0.580 0.960
LVEDV at 6th month, (mL) 99.2 ± 43.5 85.6 ± 22.9 0.223 0.848
ΔLVEDV, (%)b + 13.2 ± 22.8 −8.8 ± 14.7 0.001 0.011
aAdjusted for diabetes mellitus, hypertension, coronary reperfusion therapy and use of ACEi/ARBs drugs
bAll delta (Δ) variables were also adjusted for their baseline level at D1
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above the median had lower levels of BNP at D5 than
their counterparts. Accordingly, participants who con-
sumed ω-3 levels above the median had a smaller change
in BNP levels (ΔD5-D1) than their counterparts; this dif-
ference remained significant after adjustment.
No differences were observed in the extension of in-
farcted mass obtained by CMRi neither in the LVEF at
first and sixth months after STEMI. However, participants
who consumed ω-3 levels above the median had an in-
crease of LVEF from the first to the sixth month after
STEMI while their counterparts had a decrease of LVEF
in this period of time. Also, LVEDV was not different be-
tween the groups at the first and sixth month after
STEMI. Nevertheless, participants who consumed ω-3
levels above the median had a decrease in LVEDV from
the first to the sixth month while their counterparts had
an increase in LVEDV in the same period.
The associations between the intake of ω-3 and the
changes in the levels of BNP, LVEF and LVEDV mea-
sures were tested by binary logistic regression models as
shown in Table 3. The intake of ω-3 below the median
was inversely associated with increase in BNP levels.
Conversely, the intake of ω-3 below the median was dir-
ectly associated with reduction in LVEF and decrease in
LVEDV. Both associations remained significant after full
adjustment for covariates.
Discussion
In short, this study indicates that an increased daily in-
take of ω-3 (at least 1.7 g) is associated with attenuated
inflammatory response and ventricular remodeling after
STEMI.
Excessive increase in pro-inflammatory cytokines se-
cretion after MI have been associated with a higher risk
for mortality [30]. Clinically, hs-CRP is a has been estab-
lished as the preferred biomarker for inflammatory activ-
ity given its long half-life and its value in predicting both
the incidence of cardiovascular events and mortality
[31]. In STEMI patients, we previously observed a direct
relationship between the activation of the innate and
TH1 inflammatory response after post-reperfusion ex-
pansion of the peri-infarcted myocardial mass [29]. This
finding has motivated us to verify the effect of such in-
flammatory attenuation of the left ventricle remodeling
after STEMI. In fact, in line with prior studies in chronic
and acute disease [13–19], individuals consuming at
least 1.7 g ω-3 had a greater reduction of IL-2 (a classical
marker for Th1 response) and hs-CRP (a marker for in-
nate response) during the acute phase of MI.
Table 3 Binary logistic regression to assess the association
between daily consumption of omega-3 and Δhs-CRP, ΔIL-2,
ΔBNP, ΔLVEF and ΔLVEDV
OR(95%CI); p-value Δhs-CRP ≥ + 2.20 mg/L




ΔIL-2 ≥ + 4.642 pg/mL




ΔBNP≥ + 0.10 ng/mL




ΔLVEF < + 1.2%





Omega-3 < 1.7 g
Model 1 5.250(1.093–25.211);0.038
Model 2 2.857(1.467–6.877);0.017
Model 1: Unadjusted; Model 2: Adjusted for diabetes mellitus, hypertension,
coronary reperfusion therapy, use of ACEi/ARBs drugs, triglycerides, systolic
blood pressure, diastolic blood pressure and peak CK-MB
Fig. 2 Restricted cubic spline curves to assess for relationship between daily consumption of ω-3 and change in hs-CRP (a), IL-2 (b) and BNP
levels (c) during acute phase of STEMI (ΔCRP = D5 – D1). Splines were adjusted by the Global Registry of Acute Coronary Events (GRACE) score
and plasma peak CKMB level
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Higher intake of ω-3 before MI was associated with
higher late gain of LVEF and decreased late gain of
LVEDV, indicating a lower degree of remodeling. As the
nutritional reanalysis of these individuals three months
after STEMI continued to point to a higher consump-
tion of ω-3, we cannot rule out the possibility that per-
sistently increased consumption also contributed to this
outcome. We also cannot exclude the possibility of a
play of chance due to the observational design of this
study, precluding the balance between the groups for
variables not measured or not known. Nevertheless, the
treatment of high-dose of ω-3 after STEMI has been
shown to be associated with a reduction in left ventricu-
lar remodeling, myocardial fibrosis, and systemic inflam-
mation in a prospective randomized controlled trial [32].
This may result from the anti-inflammatory action of
these fatty acids and may also result from direct effects
of ω-3 on myocardial cells. For example, ω-3 protects
the metabolic and functional properties of cardiomyo-
cytes submitted to conditions prone to insulin resistance,
such as STEMI [33]. Also, intake of certain types of fatty
acids may modulate cardiomyocyte gene expression and,
by this way, change myocardial bioenergetics; ω-3, for
example, stimulates angiopoietin-like protein 4 resulting
in decreased cardiac absorption of fatty acids and de-
creased oxidative stress induced by fatty acids and lipid
peroxidation [34]. Thus, the toning down of both sys-
temic inflammatory activation and ventricular remodel-
ing after STEMI may result from a combination of
direct and indirect effects of ω-3.
Some limitations must be considered when reading
this study. Firstly, as commented above, our findings
must be considered as hypothesis generating due to the
observational design and hence the impossibility to ex-
clude selection bias. Randomized controlled trials (RCT)
are required to exclude unbalance between the arms and
the healthy cohort effect. However, consistency with
RCT and mechanistic data deem this finding plausible.
Other limitation that should be considered is the recall
bias due to FFQ application, since participants are asked
to report their food intake retrospectively in a prolonged
period of time.
Conclusion
In conclusion, the findings of the present study suggest
that a reduced daily intake of ω-3 may intensify
outcome-determining mechanisms after STEMI, such as
acute inflammatory response and late left ventricular
remodeling.
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